home / stock / opt / opt news

OPT News and Press, Opthea Limited From 05/01/24

Stock Information
Company Name: Opthea Limited
Stock Symbol: OPT
Market: NASDAQ
Website: opthea.com
Menu
OPT OPT Quote OPT Short OPT News OPT Articles OPT Message Board
Get OPT Alerts

News, Short Squeeze, Breakout and More Instantly...
OPT - Opthea Announces Upcoming Presentations at the Retina World Congress 2024

MELBOURNE, Australia and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, includ...
OPT - Outperform Recommendation Issued On OPT By Oppenheimer

2024-04-25 11:15:04 ET Oppenheimer analyst issues OUTPERFORM recommendation for OPT on April 25, 2024 09:26AM ET. The previous analyst recommendation was Outperform. OPT was trading at $3.43 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

OPT - Opthea to Present at the OIS Retina Innovation Summit at ARVO

MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, incl...

OPT - Opthea Appoints John Han, PharmD, as VP Medical Affairs

MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, incl...
OPT - Opthea to Participate in the 23?? Annual Needham Virtual Healthcare Conference 

MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, incl...

OPT - Opthea Appoints Sujal Shah to the Board of Directors

MELBOURNE, Australia and PRINCETON, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, incl...

OPT - Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024

MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced it will host...
OPT - Ocean Power Technologies, Inc. Announces Third Quarter Fiscal 2024 Results

MONROE TOWNSHIP, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. ("OPT" or "the Company") (NYSE American: OPTT), today announced financial results for its fiscal third quarter ended January 31, 2024 (“Q324”), including year over year revenue, gross profi...

OPT - Optiva Inc. Reports Fourth Quarter 2023 Financial Results

All amounts are stated in United States dollars unless otherwise indicated Revenue of $12.0 million Robust sales pipeline with three additional customer wins Total Contract Value (“TCV”) 1 bookings of $24.3 million Gross margin of 63% Adjusted EBITDA 1 ...

OPT - Tracking Baker Brothers Portfolio - Q4 2023 Update

2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...
Previous 10 Next 10